The receptor tyrosine kinase (RTK)-based inhibitor approaches to anti-angiogenic therapy are likely also effecting tumour RTK signalling cascades, which regulate tumour proliferation, survival, metabolism and HIF (Shimobayashi & Hall, 2014). The gene discussed is NTRK1; the disease is neoplasm.